Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study.

Blood Advances
Marie-Helene Delfau-LarueFranck Morschhauser

Abstract

Complete molecular response (CMR) after first-line immunochemotherapy reflects treatment efficacy and may predict prognosis in patients with follicular lymphoma (FL). RELEVANCE is the first phase 3 trial comparing the chemotherapy-free regimen lenalidomide/rituximab (R2) vs rituximab/chemotherapy (R-Chemo) in previously untreated FL patients (ClinicalTrials.gov identifier: NCT01650701). The objective of the minimal residual disease (MRD) analysis was to determine the ability of a chemotherapy-free regimen to induce CMR. Of 440 French patients participating in the Lymphoma Study Association (LYSA) RELEVANCE MRD study, all 222 patients with a BIOMED-2-detectable BCL2-JH translocation at diagnosis were analyzed. MRD was quantified by droplet digital polymerase chain reaction with a sensitivity ≤10-4. At week 24 (end of induction treatment), 98% and 78% of patients achieved CMR in peripheral blood (PB) and bone marrow (BM), respectively. Achievement of CMR (in PB and/or BM) had a significant impact on progression-free survival (PFS), with 3-year PFS of 84% and 55% for patients with CMR and detectable MRD, respectively (P = .015). CMR at week 24 was reached more frequently in the R2 arm (105/117; 90%) than in the R-Chemo arm (70/90;...Continue Reading

References

Aug 9, 2001·Blood·C M MandigersUNKNOWN Interzol (South-East Netherlands Comprehensive Cancer Centers Cooperative Group)
Feb 9, 2007·Leukemia·V H J van der VeldenUNKNOWN European Study Group on MRD detection in ALL (ESG-MRD-ALL)
Oct 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lindsey GoffAma Rohatiner
Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Emmanuel BachyGilles Salles
Dec 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian W ScholzAntonio Pezzutto
Jun 5, 2013·Therapeutic Advances in Hematology·Chiara Lobetti-BodoniMarco Ladetto
Oct 16, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sara GalimbertiMassimo Federico
Oct 5, 2017·The New England Journal of Medicine·Robert MarcusWolfgang Hiddemann
Sep 6, 2018·The New England Journal of Medicine·Franck MorschhauserUNKNOWN RELEVANCE Trial Investigators
Nov 8, 2018·Current Treatment Options in Oncology·Daniele GrimaldiMarco Ladetto

❮ Previous
Next ❯

Citations

Sep 2, 2020·Expert Review of Hematology·Emanuele CenciniMonica Bocchia
Feb 8, 2021·British Journal of Haematology·Rahul Lakhotia, Mark Roschewski
Nov 13, 2020·Expert Review of Hematology·Ruth Alonso-AlonsoMiguel A Piris
Mar 27, 2021·Stem Cell Research & Therapy·Margaret G LambDean A Lee
Oct 29, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefano LuminariUNKNOWN Fondazione Italiana Linfomi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.